Abstract
An overwiew is given of tjhe reasons to change immunomodulatory therapy, evaluation of disease activity and treatment effect, disease free concept is discussed, escalation regimens including pharmacovigilance provided. The rules for individualized medicine and the role of patient in this decision making process are outlined